Homocysteine and heart failure: an overview.
暂无分享,去创建一个
R. Raddino | L. Dei Cas | C. Fiorina | E. Vizzardi | I. Bonadei | S. Frattini | G. Zanini
[1] Jayesh P. Rai,et al. Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia. , 2008, American journal of physiology. Heart and circulatory physiology.
[2] S. Moat. Plasma total homocysteine: instigator or indicator of cardiovascular disease? , 2008, Annals of clinical biochemistry.
[3] S. Tyagi,et al. Mitochondrial MMP activation, dysfunction and arrhythmogenesis in hyperhomocysteinemia. , 2008, Current vascular pharmacology.
[4] S. Tyagi,et al. Cardiac dys-synchronization and arrhythmia in hyperhomocysteinemia. , 2007, Current neurovascular research.
[5] P. Ponikowski,et al. Hyperhomocysteinemia in patients with symptomatic chronic heart failure: prevalence and prognostic importance--pilot study. , 2007, Atherosclerosis.
[6] M. Metra,et al. [Raised homocysteine plasma concentration in patients with heart failure: clinical significance]. , 2007, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.
[7] N. Danchin,et al. Left ventricular systolic dysfunction is an independent predictor of homocysteine in angiographically documented patients with or without coronary artery lesions , 2007, Journal of thrombosis and haemostasis : JTH.
[8] R. Straub,et al. Hyperhomocysteinemia and myocardial expression of brain natriuretic peptide in rats. , 2007, Clinical chemistry.
[9] A. Folsom,et al. Elevated Homocysteine Is Associated With Reduced Regional Left Ventricular Function: The Multi-Ethnic Study of Atherosclerosis , 2006, Circulation.
[10] A. Pessina,et al. Homocysteine, left ventricular dysfunction and coronary artery disease: is there a link? , 2007, Clinical chemistry and laboratory medicine.
[11] S. Tyagi,et al. Homocysteine, brain natriuretic peptide and chronic heart failure: a critical review , 2007, Clinical chemistry and laboratory medicine.
[12] J. König,et al. Plasma B vitamins and their relation to the severity of chronic heart failure. , 2007, The American journal of clinical nutrition.
[13] B. Horne,et al. Homocysteine Levels Are Associated with Increased Risk of Congestive Heart Failure in Patients with and without Coronary Artery Disease , 2006, Cardiology.
[14] S. Tyagi,et al. Mitochondrial mechanism of microvascular endothelial cells apoptosis in hyperhomocysteinemia , 2006, Journal of cellular biochemistry.
[15] M. Boerma,et al. ACUTE DILATORY AND NEGATIVE INOTROPIC EFFECTS OF HOMOCYSTEINE ARE INHIBITED BY AN ADENOSINE BLOCKER , 2006, Clinical and experimental pharmacology & physiology.
[16] J. Joseph,et al. Effect of long-term hyperhomocysteinemia on myocardial structure and function in hypertensive rats. , 2006, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[17] J. Cleland,et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. , 2005, European heart journal.
[18] M. Böhm,et al. Relationship of plasma homocysteine with the severity of chronic heart failure. , 2005, Clinical chemistry.
[19] A. Hoes,et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.
[20] J. Zell,et al. Plasma homocysteine levels and the left ventricular systolic function in coronary artery disease patients , 2005, Coronary artery disease.
[21] A. Pessina,et al. Hyperhomocysteinemia Is Inversely Related With Left Ventricular Ejection Fraction and Predicts Cardiovascular Mortality in High-Risk Coronary Artery Disease Hypertensives , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[22] J. Bennett,et al. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease , 1991, Klinische Wochenschrift.
[23] R. Vasan,et al. Risk factors for heart failure. , 2004, The Medical clinics of North America.
[24] Albert Hofman,et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. , 2004, European heart journal.
[25] J. Joseph,et al. Acute negative inotropic effects of homocysteine are mediated via the endothelium. , 2004, American journal of physiology. Heart and circulatory physiology.
[26] D. Levy,et al. Relations of plasma homocysteine to left ventricular structure and function: the Framingham Heart Study. , 2004, European heart journal.
[27] S. Tyagi,et al. Reduction-oxidation (Redox) and vascular tissue level of homocyst(e)ine in human coronary atherosclerotic lesions and role in extracellular matrix remodeling and vascular tone , 1998, Molecular and Cellular Biochemistry.
[28] M. Lesch,et al. Progression of heart failure: A role for interstitial fibrosis , 1995, Molecular and Cellular Biochemistry.
[29] J. Aranda,et al. Hyperhomocysteinemia in patients with heart failure referred for cardiac transplantation: Preliminary observations , 2003, Clinical cardiology.
[30] D. Modai,et al. Dietary Intake of Various Nutrients in Older Patients with Congestive Heart Failure , 2003, Cardiology.
[31] M. Hauer-Jensen,et al. Hyperhomocysteinemia leads to pathological ventricular hypertrophy in normotensive rats. , 2003, American journal of physiology. Heart and circulatory physiology.
[32] H. McNulty,et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. , 2003, Blood.
[33] D. Levy,et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. , 2003, JAMA.
[34] J. Erikssen,et al. Plasma total homocysteine levels and prognosis in patients with previous premature myocardial infarction: a 10‐year follow‐up study , 2003, Journal of internal medicine.
[35] L. Fink,et al. Hyperhomocysteinemia leads to adverse cardiac remodeling in hypertensive rats. , 2002, American journal of physiology. Heart and circulatory physiology.
[36] Z. Ungvari,et al. Impaired nitric oxide-mediated flow-induced coronary dilation in hyperhomocysteinemia: morphological and functional evidence for increased peroxynitrite formation. , 2002, The American journal of pathology.
[37] S. Tyagi,et al. Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. , 2002, American journal of hypertension.
[38] M. Kostrubiec,et al. Homocysteine, Adrenergic Activity and Left Ventricular Mass in Patients with Essential Hypertension , 2002, Blood pressure.
[39] G. Salvioli,et al. Hyperhomocysteinemia and related factors in 600 hospitalized elderly subjects. , 2001, Metabolism: clinical and experimental.
[40] P. Tsao,et al. Homocysteine Impairs the Nitric Oxide Synthase Pathway: Role of Asymmetric Dimethylarginine , 2001, Circulation.
[41] J. Loscalzo,et al. Overexpression of cellular glutathione peroxidase rescues homocyst(e)ine-induced endothelial dysfunction , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[42] K. Swedberg,et al. Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.
[43] J. Cleland,et al. The heart failure epidemic: exactly how big is it? , 2001, European heart journal.
[44] W. Kisiel,et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. , 2001, The Journal of clinical investigation.
[45] S. Vollset,et al. The Hordaland Homocysteine Studies , 2001, Lipids.
[46] P. Collinson,et al. Elevated homocysteine levels are associated with increased ischemic myocardial injury in acute coronary syndromes. , 2000, Journal of the American College of Cardiology.
[47] J. Loscalzo,et al. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. , 2000, The Journal of clinical investigation.
[48] P. Binkley,et al. Plasma atherogenic markers in congestive heart failure and posttransplant (heart) patients. , 2000, Journal of the American College of Cardiology.
[49] M. Ávila,et al. Induction of TIMP-1 expression in rat hepatic stellate cells and hepatocytes: a new role for homocysteine in liver fibrosis. , 1999, Biochimica et biophysica acta.
[50] S. Yusuf,et al. Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence , 1999, Annals of Internal Medicine.
[51] J. Blacher,et al. Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. , 1999, Journal of nephrology.
[52] S. Tyagi. Homocyst(e)ine and heart disease: pathophysiology of extracellular matrix. , 1999, Clinical and experimental hypertension.
[53] J. Michel,et al. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. , 1999, Cardiovascular research.
[54] A Hofman,et al. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. , 1999, European heart journal.
[55] I. Alfheim,et al. Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. , 1998, Clinical chemistry.
[56] J. Loscalzo,et al. Homocysteine-induced nitric oxide production in vascular smooth-muscle cells by NF-kappa B-dependent transcriptional activation of Nos2. , 1998, Proceedings of the Association of American Physicians.
[57] S. Vollset,et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. , 1997, The New England journal of medicine.
[58] A. Majors,et al. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[59] S. Lentz,et al. Homocysteine and vascular dysfunction. , 1997, Life sciences.
[60] J. Loscalzo,et al. Homocyst(e)ine Decreases Bioavailable Nitric Oxide by a Mechanism Involving Glutathione Peroxidase* , 1997, The Journal of Biological Chemistry.
[61] J. Witteman,et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. , 1997, JAMA.
[62] J. Loscalzo. The oxidant stress of hyperhomocyst(e)inemia. , 1996, The Journal of clinical investigation.
[63] R. Vasan,et al. The progression from hypertension to congestive heart failure. , 1996, JAMA.
[64] M. Weinstock,et al. Relationship among homocyst(e)ine, vitamin B-12 and cardiac disease in the elderly: association between vitamin B-12 deficiency and decreased left ventricular ejection fraction. , 1996, The Journal of nutrition.
[65] C. H. Conrad,et al. The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure. , 1995, Journal of molecular and cellular cardiology.
[66] M. Bristow,et al. Economic impact of heart failure in the United States: time for a different approach. , 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[67] K. Mccully,et al. Homocysteine metabolism and the oxidative modification of proteins and lipids. , 1993, Free radical biology & medicine.
[68] J. Stamler,et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. , 1993, The Journal of clinical investigation.
[69] W. Willett,et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. , 1992, JAMA.
[70] K. Weber,et al. Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.
[71] R. Clarke,et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. , 1991, The New England journal of medicine.
[72] P. Wilson,et al. Plasma homocyst(e)ine levels in men with premature coronary artery disease. , 1990, Journal of the American College of Cardiology.